NCT02186977View on ClinicalTrials.gov

Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Hepatitis B
Interventions
DEVICE

VAX-ID

0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection

DRUG

1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)

1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)

DRUG

0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)

0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection

Trial Locations (1)

2610

Centre for the Evaluation of Vaccination Vaccine & Infectious Disease Institute, Wilrijk

Sponsors

Lead Sponsor

Novosanis NV
All Listed Sponsors
lead

Novosanis NV

INDUSTRY

NCT02186977 - Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID | Biotech Hunter | Biotech Hunter